GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
$172.36
+0 (+0%)
At Close: Dec 22, 2023
Forecast Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $172.36 $172.36 Friday, 22nd Dec 2023 RETA stock ended at $172.36. During the day the stock fluctuated 0% from a day low at $172.36 to a day high of $172.36.
90 days $172.32 $172.46
52 weeks $26.26 $172.46

Historical RETA prices

Date Open High Low Close Volume
2023-09-07 $169.56 $170.26 $169.56 $170.15 690 016
2023-09-06 $169.38 $169.77 $169.38 $169.63 318 651
2023-09-05 $168.67 $169.98 $168.67 $169.79 642 411
2023-09-01 $168.90 $169.50 $168.90 $169.26 362 174
2023-08-31 $168.84 $169.26 $168.82 $169.00 550 595
2023-08-30 $169.14 $169.17 $168.67 $168.70 456 492
2023-08-29 $169.19 $169.20 $168.80 $168.88 622 915
2023-08-28 $169.11 $169.30 $168.86 $168.90 645 982
2023-08-25 $169.10 $169.27 $168.82 $169.00 363 142
2023-08-24 $169.20 $169.37 $168.56 $168.75 593 244
2023-08-23 $169.25 $169.48 $169.10 $169.16 508 644
2023-08-22 $169.25 $169.55 $169.09 $169.25 951 601
2023-08-21 $169.50 $169.50 $169.03 $169.24 627 271
2023-08-18 $169.00 $169.34 $168.77 $169.26 707 367
2023-08-17 $168.80 $169.29 $168.63 $169.00 502 869
2023-08-16 $168.96 $169.40 $168.28 $169.06 1 088 295
2023-08-15 $169.00 $169.48 $168.76 $169.13 756 916
2023-08-14 $168.00 $169.74 $168.00 $169.27 1 366 608
2023-08-11 $167.30 $168.00 $167.11 $167.48 338 211
2023-08-10 $167.30 $167.85 $166.99 $167.05 486 577
2023-08-09 $167.48 $168.69 $167.00 $167.11 1 363 541
2023-08-08 $166.70 $167.60 $166.50 $167.16 986 980
2023-08-07 $166.50 $167.09 $166.05 $166.42 1 569 004
2023-08-04 $166.95 $167.21 $166.12 $166.39 670 387
2023-08-03 $166.21 $167.51 $165.86 $167.16 1 152 690
Click to get the best stock tips daily for free!

About RETA

RETA Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated ... RETA Profile

Golden Star

Ticker Date Change Price
ITCI Apr 05 12.05% $68.44
AKR Apr 05 0.665% $16.53
SARK Mar 28 16.07% $26.88
ARCC Mar 25 1.04% $20.12
STT Mar 19 0.262% $72.62
GGB Mar 19 0.468% $4.27
CAG Mar 18 7.16% $28.22
JBI Mar 15 1.29% $14.72
MASI Mar 14 3.34% $132.20
CMC Mar 14 5.04% $53.19
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT